Final results for the 16-months ending 31.03.2025

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

30 September 2025

AMIROSE LONDON HOLDINGS PLC

(''Amirose'' or the "Company'')

FINAL RESULTS FOR THE 16-MONTHS ENDING 31 MARCH 2025

Amirose London Holdings PLC is pleased to announce its results for the year ended 31 March 2025. The results relate to the activities of File Forge Technology PLC prior to its acquisition of Amirose London Limited in a reverse takeover transaction which completed on 6 June 2025 ("Transaction"). File Forge Technology PLC was renamed Amirose London Holdings PLC. Following completion of the Transaction, the Company's strategy and operations have fundamentally changed.

For further information, please contact:

Chairman's Statement

Dear Shareholders,

I am delighted to present the results of Amirose London Holdings PLC (formerly File Forge Technology PLC and Clarify Pharma PLC) for the 16-month period ended 31 March 2025. This has been a defining chapter in the Company's journey,  marked by decisive change, a sharpened sense of purpose, and the laying of foundations for sustainable long-term growth.

Having originally pursued a strategy in the decentralised storage sector, the previous Board reached the view that this model did not offer the most effective pathway to shareholder value. After careful consideration, the previous Board concluded that greater potential lay in acquiring an established operating business with a proven revenue base, long-standing customer relationships, and genuine scalability.

In June 2025, the Company completed the reverse takeover of Amirose London Limited, a contract manufacturer with a distinguished track record in the personal care sector. For decades, Amirose has supplied some of the most recognised brands from its facility in Thetford, Norfolk, reaching local and global markets. Its reputation is built not only on product quality but also on reliability, flexibility, and the ability to adapt quickly to client needs. Alongside this transaction, the Company adopted a new name, Amirose London Holdings PLC.

The results for the reporting period demonstrate the impact of this new direction. The Company recorded a total comprehensive income of £24,000, a significant turnaround from the prior year's total comprehensive loss of £810,000. This reflects both disciplined cost management and the orderly disposal of non-core assets. More importantly, it validates our conviction that Amirose represents a platform with the ability to deliver both financial stability and growth.

Looking forward, the opportunity before us is compelling and exciting.  Amirose operates a high-margin, mid-volume production model, which positions us to serve a growing number of personal care brands that value agility, quality, and trust over sheer scale. With shifting consumer demand, supply chain realignment, and an increased emphasis on domestic and near-shore production, we see a market environment that plays directly to our strengths.

Equally transformative has been the strengthening of our Board. The reconstituted Board now brings not only deep governance and financial expertise, gained from service on numerous public company boards, but also invaluable operational experience from successful manufacturing businesses. In addition, the new Board has created a plethora of connections across the personal care industry and new avenues in the sector. These relationships are already opening doors and presenting new opportunities.

The geopolitical environment, while challenging, has also created a change in global supply chains, and we are well placed to capture business flows that might previously have gone elsewhere.

The untapped potential of this network, combined with our established reputation and facility, gives us confidence that the next stage of growth can be both meaningful and enduring. We will continue to invest in strengthening customer partnerships, upgrading our manufacturing capabilities, and building on the trust that Amirose has cultivated over decades.

On behalf of the new Board of Amirose London Holdings PLC, I wish to thank you, our shareholders, for your continued support and belief as we transition into this exciting new era.

Aleksandra Binkowska

Non-Executive Chairman

Date:  29 September 2025

Statement of Comprehensive Income for the 16-months period ending 31 March 2025

Statement of Financial position as at 31 March 2025

Cash Flow Statement for the 16-months period ending 31 March 2025

NOTES TO PRELIMINARY RESULTS FOR THE PERIOD ENDED 31 March 2025

1.    The financial information set out above does not constitute statutory accounts for the purpose of Section 434 of the Companies Act 2006. The financial information has been extracted from the statutory accounts of Amirose London Holdings PLC and is presented using the same accounting policies, which have not yet been filed with the Registrar of companies, but on which the auditors gave an unqualified report on 29 September 2025.

The preliminary announcement of the results for the year ended 31 March 2025 was approved by the board of directors on 29 September 2025.

2.         Earnings per Share

- ends -

The Directors accept responsibility for this announcement.

About Amirose London Holdings PLC  

Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands. Amirose will assist such brands in developing formulations for personal care products, sourcing packaging, bulk manufacturing, filling and distributing. Amirose also helps customers navigate the regulatory and compliance framework required to bring a product to market. Amirose has approximately 75 customers and services over 200 brands. Amirose's manufacturing facilities are in Thetford, Norfolk. Amirose currently has 86 employees. 

Amirose aims to transform its contract manufacturing business, which has so far generated modest profits while utilising only a portion of its factory's capacity, into a thriving enterprise by fully leveraging excess capacity, infrastructure, and the expertise of its team. Amirose expects to drive growth organically and through strategic acquisitions in the future. 

For more information on the Company please visit www.amiroselondon.com